AAV-ULK1 gene therapy

AAV-ULK1 gene therapy has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Feb 6, 2026: “Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on AAV-ULK1 gene therapy

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: Beijing Municipal Natural Science Foundation and 4 more
  • Animals1

What did studies of AAV-ULK1 gene therapy find?

1

Studies of AAV-ULK1 gene therapy measured one outcome, heart failure with preserved ejection fraction.

Heart failure with preserved ejection fraction

downin mice1

1 study
  1. AAV-ULK1 gene therapy decreases heart failure with preserved ejection fraction in mice with HFpEF.

    “ULK1 overexpression via AAV-9 attenuated the HFpEF phenotype in mice.”

    Animalsin mice with HFpEFheartmales

    Small extracellular vesicle-mediated adipocyte-cardiomyocyte crosstalk exacerbates heart failure with preserved ejection fraction

    Cardiovascular research

More on Heart failure with preserved ejection fraction

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months